Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

NCT06092606 is registered in ClinicalTrials.gov with Monyan Pharmaceutical (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06092606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06092606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Lead sponsor
Monyan Pharmaceutical (Shanghai) Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
April 4, 2023
Completion date
January 31, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmia, cancer, doxorubicin adverse reaction, doxorubicin induced cardiomyopathy, heart failure